vTv Therapeutics Inc.
VTVT
$22.23
-$0.27-1.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -431.06% | 14.16% | 106.67% | -32.80% | -46.06% |
| Gross Profit | 432.65% | -14.16% | -106.67% | 58.17% | 45.94% |
| SG&A Expenses | 4.13% | 29.01% | 12.30% | 14.15% | 7.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.29% | 21.20% | -10.56% | -10.77% | -25.90% |
| Operating Income | -3.93% | -21.20% | 10.56% | 24.24% | 25.79% |
| Income Before Tax | 0.09% | 31.62% | 11.12% | -2.51% | 27.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.09% | 31.62% | 11.12% | -4.24% | 27.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -16.61% | -43.96% | -22.80% | -9.49% | -28.40% |
| Net Income | -4.49% | 28.12% | 7.81% | -8.14% | 26.70% |
| EBIT | -3.93% | -21.20% | 10.56% | 24.24% | 25.79% |
| EBITDA | -3.97% | -21.29% | 10.59% | 24.31% | 25.89% |
| EPS Basic | 66.91% | 72.53% | 69.99% | 7.33% | 28.39% |
| Normalized Basic EPS | 65.77% | 71.29% | 68.98% | 36.83% | 14.94% |
| EPS Diluted | 66.91% | 72.53% | 69.99% | 7.33% | 28.39% |
| Normalized Diluted EPS | 65.77% | 71.29% | 68.98% | 36.83% | 14.94% |
| Average Basic Shares Outstanding | 215.72% | 161.69% | 207.12% | 16.69% | 2.35% |
| Average Diluted Shares Outstanding | 215.72% | 161.69% | 207.12% | 16.69% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |